Canada approves AMDL's cancer blood test:
This article was originally published in Clinica
Executive Summary
Theranostics company AMDL has gained the go-ahead to market its cancer blood test, DR-70, in Canada. The test can detect up to 13 cancers using a single tube of blood, reducing the need for costly, multiple tests, says the Tustin, California firm. "Already, several potential distributors have shown serious interest in the Canadian market and AMDL can now accelerate those discussions," said Gary Dreher, the company's president and CEO.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.